RYE BROOK, NY--(Marketwired - August 14, 2014) - In a move that further demonstrates its commitment to continuously enhance its renowned cytopathology program, CBLPath, a Sonic Healthcare USA laboratory, is pleased to announce that it has hired three new cytopathologists to help meet growing demand for its services. Drs. Hani Hojjati, Antonio Macias and Sofia Kazi will join CBLPath's world-class cytopathology department, led by Madeline Vazquez, M.D. CBLPath's cytopathology department is one of the largest programs in the United States for the interpretation of thyroid fine needle aspiration biopsies.
Dr. Hani Hojjati received her M.D. degree from Shahid Beheshti University of Medical Sciences in Tehran, Iran and is board certified in anatomic pathology by the American Board of Pathology. She started her pathology residency at Cedars Sinai Medical Center in Los Angeles, California and completed her residency in anatomic pathology at Weill Cornell Medical College/New York Presbyterian Hospital in New York. After her residency, Dr. Hojjati then completed a fellowship in surgical pathology at Hartford Hospital in Hartford, Connecticut, followed by a fellowship in cytopathology at the University of Florida in Jacksonville.
Dr. Antonio Macias is board certified in anatomic and clinical pathology and cytopathology. He received his M.D. degree from the Autonomous University of Aguascalientes in Aguascalientes, Mexico, followed by an internship in internal medicine at Miguel Hidalgo Hospital in Aguascalientes, Mexico. He then completed his anatomic and clinical pathology residency at Albert Einstein College of Medicine at Long Island Jewish Medical Center where he served as Chief Resident. After his residency, Dr. Macias completed fellowships in oncologic surgical pathology and cytopathology at Memorial Sloan-Kettering Cancer Center. After his fellowships, Dr. Macias served as Attending Surgical Pathologist, Cytopathologist and on the Pathology Residency Program committee at Mount Sinai Roosevelt Hospital in New York.
Dr. Sofia Kazi graduated magna cum laude with her B.S. degree from the University of Florida and went on to earn her M.D. degree from the University of Pittsburgh School of Medicine. She then went on to complete her residency in anatomic and clinical pathology at Mount Sinai Medical Center where she served as Chief Resident. Following her residency, she completed a fellowship in cytopathology at Memorial Sloan-Kettering Cancer Center, where she trained under several world-renowned pathologists. Dr. Kazi is board certified in anatomic and clinical pathology by the American Board of Pathology.
"Demand for our services quickly increased after we announced our preferred partnership agreement with the University of Pittsburgh Medical Center (UPMC) Division of Molecular and Genomic Pathology to become the only commercial lab to offer UPMC's revolutionary next generation sequencing assay ThyroSeq™ v.2," said CBLPath Co-CEO and Chief Medical Officer, Dr. Carlos D. Urmacher, FCAP, FASCP. "CBLPath is excited to welcome Drs. Hani Hojjati, Antonio Macias and Sofia Kazi to its team to help us meet increasing demand for our services."
To speak with a local CBLPath representative, call 877.225.7284. To see the company's entire array of tests, visit www.CBLPath.com and click the Test Menu link.
CBLPath, a Sonic Healthcare USA laboratory, is a leading pathology services provider, combining anatomic pathology with advanced molecular diagnostics, esoteric testing and digital pathology. CBLPath is committed to helping our clients deliver better medicine, faster. At our core are pathologists; excited about technology and innovation and its promise of helping patients. We integrate comprehensive diagnostic, prognostic and theranostic testing to deliver personalized medicine and we provide our subspecialty physician clients timely, accurate results enabling the most effective patient care. For more about the company, please visit CBLPath.com.
Documents and/or Photos available for this release:
pdf of Cytopathology Expansion Press Release
To view supporting documents and/or photos, go to www.enr-corp.com/pressroom and enter Release ID: 376701